Tags

Type your tag names separated by a space and hit enter

Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.
Clin Infect Dis. 2011 Jan 01; 52(1):122-7.CI

Abstract

BACKGROUND

To determine the rate of seroconversion after 2 doses of a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in human immunodeficiency virus type 1 (HIV-1)-infected patients (ClinicalTrials.gov NCT01017172).

METHODS

Diagnostic study of adult HIV-1-infected patients scheduled for H1N1 influenza A vaccination. Blood samples where taken before and 21 days after the first dose and 21 days after the second dose of the vaccine. Antibody (AB) titers were determined by hemagglutination inhibition assay. Seroconversion was defined by either an AB titer ≤ 1:10 before and ≥ 1:40 after or ≥ 1:10 before and a ≥ 4-fold increase in AB titer 21 days after vaccination.

RESULTS

One hundred thirty-five patients received 2 doses of the H1N1 vaccine and were analyzed. The rate of seroconversion was 68.2% (95% confidence interval, 59.6-75.9) after the first dose and 91.9% (95% confidence interval, 85.9-95.9) after the second dose. Patients who did not seroconvert had a lower mean nadir CD4 cell count (± standard deviation; 81 ± 99 vs 190 ± 148 cells/μL; P = .006), had a longer duration of HIV infection (± standard deviation; 13.1 ± 5.9 vs 8.8 ± 6.8 years; P = .04), and were more likely to have an AB titer ≥ 1:40 before vaccination (4% vs 55%; P < .001) when compared with patients with seroconversion. No other differences were found between the 2 groups, including AIDS status, highly active antiretroviral therapy status, HIV RNA - polymerase chain reaction load <50 copies/mL, CD4 cell count, sex, body mass index, and chronic hepatitis.

CONCLUSION

Among HIV-infected patients, the rate of seroconversion after the first dose of an adjuvanted H1N1 influenza A vaccine was 68% and increased to 92% after a second doses.

Authors+Show Affiliations

HIVCENTER, Clinic of the Goethe University, Frankfurt, Germany. markus.bickel@hivcenter.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21148530

Citation

Bickel, Markus, et al. "Immune Response After Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza a Vaccine in HIV-1-infected Patients." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 52, no. 1, 2011, pp. 122-7.
Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52(1):122-7.
Bickel, M., von Hentig, N., Wieters, I., Khaykin, P., Nisius, G., Haberl, A., Stephan, C., Herrmann, E., Doerr, H. W., Brodt, H. R., & Allwinn, R. (2011). Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 52(1), 122-7. https://doi.org/10.1093/cid/ciq003
Bickel M, et al. Immune Response After Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza a Vaccine in HIV-1-infected Patients. Clin Infect Dis. 2011 Jan 1;52(1):122-7. PubMed PMID: 21148530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. AU - Bickel,Markus, AU - von Hentig,Nils, AU - Wieters,Imke, AU - Khaykin,Pavel, AU - Nisius,Gabi, AU - Haberl,Annette, AU - Stephan,Christoph, AU - Herrmann,Eva, AU - Doerr,Hans W, AU - Brodt,Hans Reinhard, AU - Allwinn,Regina, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/3/29/medline SP - 122 EP - 7 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 52 IS - 1 N2 - BACKGROUND: To determine the rate of seroconversion after 2 doses of a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in human immunodeficiency virus type 1 (HIV-1)-infected patients (ClinicalTrials.gov NCT01017172). METHODS: Diagnostic study of adult HIV-1-infected patients scheduled for H1N1 influenza A vaccination. Blood samples where taken before and 21 days after the first dose and 21 days after the second dose of the vaccine. Antibody (AB) titers were determined by hemagglutination inhibition assay. Seroconversion was defined by either an AB titer ≤ 1:10 before and ≥ 1:40 after or ≥ 1:10 before and a ≥ 4-fold increase in AB titer 21 days after vaccination. RESULTS: One hundred thirty-five patients received 2 doses of the H1N1 vaccine and were analyzed. The rate of seroconversion was 68.2% (95% confidence interval, 59.6-75.9) after the first dose and 91.9% (95% confidence interval, 85.9-95.9) after the second dose. Patients who did not seroconvert had a lower mean nadir CD4 cell count (± standard deviation; 81 ± 99 vs 190 ± 148 cells/μL; P = .006), had a longer duration of HIV infection (± standard deviation; 13.1 ± 5.9 vs 8.8 ± 6.8 years; P = .04), and were more likely to have an AB titer ≥ 1:40 before vaccination (4% vs 55%; P < .001) when compared with patients with seroconversion. No other differences were found between the 2 groups, including AIDS status, highly active antiretroviral therapy status, HIV RNA - polymerase chain reaction load <50 copies/mL, CD4 cell count, sex, body mass index, and chronic hepatitis. CONCLUSION: Among HIV-infected patients, the rate of seroconversion after the first dose of an adjuvanted H1N1 influenza A vaccine was 68% and increased to 92% after a second doses. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/21148530/Immune_response_after_two_doses_of_the_novel_split_virion_adjuvanted_pandemic_H1N1_influenza_A_vaccine_in_HIV_1_infected_patients_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciq003 DB - PRIME DP - Unbound Medicine ER -